[Swiss registry for patients with cystic fibrosis: design, programming, implementation and first examples of use].
The Swiss Registry for Cystic Fibrosis (SRCF) was designed to collect demographic, clinical and therapeutic data from patients with cystic fibrosis (CF) in Switzerland. It was designed, programmed and implemented for standalone application in Swiss cystic fibrosis centres. It is part of the European Registry for Cystic Fibrosis (ERCF), which has been implemented in Europe to collect data on the use and safety of dornase alpha (Pulmozyme) in the treatment of cystic fibrosis. At the time of first evaluation 245 cystic fibrosis patients are registered, their mean age is 13 years, and 17% are over 18. In larger databases in Germany or North America we observe comparable demographic data, similar degrees of severity and similar therapeutic approaches to those in Swiss cystic fibrosis patients. The aim of the Swiss Registry is to cover the maximum possible number of cystic fibrosis patients from this country.
Schöni-Affolter
F
F
Universitäts-Kinderklinik Bern.
Oswald
P
P
Wandt-Baumann
C
C
Kriemler
S
S
Schöni
M H
MH
D000293:Adolescent; D000328:Adult; D003550:Cystic Fibrosis / Q000453:epidemiology* / Q000628:therapy*; D019992:Databases as Topic; D003710:Demography; D003850:Deoxyribonuclease I / Q000627:therapeutic use; D005060:Europe; D005100:Expectorants / Q000627:therapeutic use; D005260:Female; D006801:Humans; D008297:Male; D011994:Recombinant Proteins / Q000627:therapeutic use; D012042:Registries; D013557:Switzerland / Q000453:epidemiology
D005100:Expectorants; D011994:Recombinant Proteins; C085693:DNASE1 protein, human; D003850:Deoxyribonuclease I